Cargando…
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines
It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible preventi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115789/ https://www.ncbi.nlm.nih.gov/pubmed/35417285 http://dx.doi.org/10.1080/21645515.2022.2037384 |
_version_ | 1784709991439007744 |
---|---|
author | Jamshidi, Elham Asgary, Amirhossein Shafiekhani, Paria Khajeamiri, Yasaman Mohamed, Kawthar Esmaily, Hadi Jamal Rahi, Sahand Mansouri, Nahal |
author_facet | Jamshidi, Elham Asgary, Amirhossein Shafiekhani, Paria Khajeamiri, Yasaman Mohamed, Kawthar Esmaily, Hadi Jamal Rahi, Sahand Mansouri, Nahal |
author_sort | Jamshidi, Elham |
collection | PubMed |
description | It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively. |
format | Online Article Text |
id | pubmed-9115789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91157892022-05-18 Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines Jamshidi, Elham Asgary, Amirhossein Shafiekhani, Paria Khajeamiri, Yasaman Mohamed, Kawthar Esmaily, Hadi Jamal Rahi, Sahand Mansouri, Nahal Hum Vaccin Immunother Coronavirus – Review It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively. Taylor & Francis 2022-04-13 /pmc/articles/PMC9115789/ /pubmed/35417285 http://dx.doi.org/10.1080/21645515.2022.2037384 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Coronavirus – Review Jamshidi, Elham Asgary, Amirhossein Shafiekhani, Paria Khajeamiri, Yasaman Mohamed, Kawthar Esmaily, Hadi Jamal Rahi, Sahand Mansouri, Nahal Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
title | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
title_full | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
title_fullStr | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
title_full_unstemmed | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
title_short | Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines |
title_sort | longevity of immunity following covid-19 vaccination: a comprehensive review of the currently approved vaccines |
topic | Coronavirus – Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115789/ https://www.ncbi.nlm.nih.gov/pubmed/35417285 http://dx.doi.org/10.1080/21645515.2022.2037384 |
work_keys_str_mv | AT jamshidielham longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT asgaryamirhossein longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT shafiekhaniparia longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT khajeamiriyasaman longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT mohamedkawthar longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT esmailyhadi longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT jamalrahisahand longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines AT mansourinahal longevityofimmunityfollowingcovid19vaccinationacomprehensivereviewofthecurrentlyapprovedvaccines |